Intel stock extends gains after report of possible U.S. government stake
Fortrea Holdings (FTRE) stock has reached a 52-week low, trading at $8.94, as investors respond to a challenging year for the company. According to InvestingPro data, the stock’s technical indicators suggest oversold conditions, while analysts maintain price targets ranging from $10 to $15.50, indicating potential upside. The latest price level reflects a significant downturn from previous periods, with the stock experiencing a precipitous 1-year change, plummeting by -77.65%. This sharp decline has raised concerns among shareholders and market analysts alike, as they assess the company’s performance and future prospects. However, management has shown confidence through aggressive share buybacks, and InvestingPro analysis indicates strong free cash flow yield at 29%. Fortrea Holdings’ journey to this 52-week low underscores the volatility and the pressures faced by the firm in a competitive and ever-changing economic landscape. Despite current challenges, InvestingPro forecasts point to improved profitability this year, with 10+ additional exclusive insights available to subscribers through detailed Pro Research Reports.
In other recent news, Fortrea Holdings reported lower-than-expected fourth-quarter earnings, with an EPS of $0.18, falling short of the analyst estimate of $0.42. The company’s revenue for the quarter was $697 million, below the consensus estimate of $813 million, marking a decline from the previous year’s $709.7 million. Fortrea’s full-year guidance for 2025 anticipates revenues between $2.45 billion and $2.55 billion, significantly below the consensus estimate of $2.74 billion. Fitch Ratings downgraded Fortrea’s credit rating from ’BB-’ to ’B’ due to a weakening credit profile and reduced growth prospects, with a negative outlook for the future. Analysts at TD Cowen and Citi also revised their price targets for Fortrea, lowering them to $11 and $12, respectively, while maintaining a Hold and Neutral rating. Fortrea recently appointed Erin L. Russell as a Class II director, bringing her extensive finance and healthcare experience to the board. The company is actively implementing cost-saving measures, particularly in SG&A expenses, aiming for net savings of $40-50 million annually. Despite these efforts, Fitch predicts a 7.3% revenue decline in 2025, with gradual recovery expected in 2026. The company’s CEO highlighted an improved book-to-bill ratio for the fourth quarter, yet the financial results indicate a challenging period ahead.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.